TScan Therapeutics (TCRX) AI Stock Analysis

• Market Cap: $75.27M
• Dividend Yield: N/A
• Average Volume (3M): 427.76K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.45
• Revenue Growth: -70.15%
• EPS Growth: N/A
• Country: US
• Employees: 200
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.26
• Shares Outstanding: 52,314,037
• 10 Day Avg. Volume: 258,692
• 30 Day Avg. Volume: 427,762
• PEG Ratio: 0.14
• Price to Book (P/B): 0.64
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.63
• Enterprise Value/Market Cap: -0.13
• Enterprise Value/Revenue: -0.24
• Enterprise Value/Gross Profit: 35.61
• Enterprise Value/Ebitda: 0.02
• 1Y Price Target: $9.33
• Price Target Upside: 628.91% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

TScan Therapeutics faces significant financial challenges, with declining revenues, negative profitability, and poor cash flow management. The technical indicators suggest continued bearish momentum, and its negative valuation metrics further diminish its investment appeal. The company needs strategic improvements to enhance its financial and market performance.

Positive Factors

Financial Position

The company ended with $252M in cash, supporting operations into 1Q:27.

Regulatory Support

The FDA appears supportive of the proposed primary endpoint for the trial, which is relapse-free survival.

Safety and Efficacy

TScan builds momentum in heme with clean safety and early efficacy signals.

Negative Factors

Market Environment

Valuation framework is adjusted to reflect a more risk-averse market environment.

TScan Therapeutics Business Overview & Revenue Model

Company Description

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

How the Company Makes Money

TScan Therapeutics makes money primarily through the development and commercialization of its TCR-engineered T-cell therapy products. Key revenue streams include research and development collaborations, partnerships with larger pharmaceutical companies, and potential future sales of its proprietary therapies. TScan may also receive milestone payments and royalties from partners as their therapies progress through clinical trials and, if successful, enter the market. Additionally, the company might secure funding through grants and government programs aimed at advancing cancer treatment research.

TScan Therapeutics Financial Statement Overview

Summary

TScan Therapeutics faces significant financial challenges with ongoing losses and cash flow deficits. Revenue growth is present but insufficient to offset operational losses. The balance sheet shows increasing equity but is heavily leveraged, indicating a need for revenue enhancement and cost control.

Income Statement

The company is experiencing negative profitability with gross and net losses. Revenue growth is observed, but it is overshadowed by increasing losses. Margins are negative, indicating the company is not currently profitable, and the EBIT and EBITDA margins reflect significant operating losses. The trend suggests a challenging financial trajectory with a need to control expenses and improve revenue generation.

Balance Sheet

The balance sheet shows high leverage with an improving equity position, as seen in the positive shift in stockholders' equity. The Debt-to-Equity ratio indicates significant borrowing, while the equity ratio reflects a moderate equity position. The trend suggests some stability in asset management, but the high degree of leverage poses risks, especially in a volatile industry like biotechnology.

Cash Flow

Operating cash flows are negative, and there is a consistent outflow in free cash flow, reflecting ongoing cash burn. However, the financing activities seem to sustain the cash position. The Free Cash Flow Growth Rate is negative, indicating increasing cash outflows. The cash flow situation highlights a reliance on external financing and the need for improved cash management.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.82M	21.05M	13.54M	10.14M	1.08M
	Gross Profit
2.82M	-67.10M	8.40M	6.81M	-19.49M
	EBIT
-134.82M	-93.46M	-66.64M	-48.64M	-26.23M
	EBITDA
-119.74M	-80.10M	-59.91M	-45.30M	-25.00M
	Net Income Common Stockholders
-127.50M	-89.22M	-65.81M	-48.63M	-26.02M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
290.11M	192.04M	120.03M	161.41M	34.79M
	Total Assets
371.12M	272.15M	199.09M	188.11M	49.74M
	Total Debt
97.38M	92.43M	85.98M	6.04M	7.43M
	Net Debt
-81.31M	-40.93M	-34.04M	-155.36M	-27.36M
	Total Liabilities
130.15M	121.28M	99.66M	27.33M	92.20M
	Stockholders Equity
240.97M	150.87M	99.43M	160.78M	-42.46M
Cash Flow		Free Cash Flow
-114.65M	-64.50M	-70.73M	-58.62M	-7.26M
	Operating Cash Flow
-110.82M	-61.36M	-66.50M	-48.68M	-3.02M
	Investing Cash Flow
-52.61M	-60.76M	-4.22M	-9.94M	-4.24M
	Financing Cash Flow
208.76M	135.44M	29.36M	189.67M	288.00K

TScan Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TCRX, the sentiment is Negative. The current price of 1.28 is below the 20-day moving average (MA) of 1.48, below the 50-day MA of 1.50, and below the 200-day MA of 3.61, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 39.95 is Neutral, neither overbought nor oversold. The STOCH value of 18.73 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TCRX.

TScan Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.14B	3.39	-43.55%	2.83%	16.49%	-0.19%
TCRX	44 Neutral	$75.27M	―	-78.93%	―	-70.15%	―
ADVM	41 Neutral	$46.27M	―	-144.41%	―	-72.22%	51.40%
CNTX	37 Underperform	$73.56M	―	-55.59%	―	―	65.02%
ADAG	36 Underperform	$81.03M	―	-55.14%	―	-99.43%	-69.40%
RANI	32 Underperform	$35.27M	―	-1372.59%	―	―	20.85%
ELTX	30 Underperform	$91.09M	―	-744.59%	―	―	27.65%

TScan Therapeutics Corporate Events

TScan Therapeutics Secures $52.5M Loan from SVB

TScan Therapeutics has entered a new loan agreement with Silicon Valley Bank, securing up to $52.5 million to refinance existing debt and fund corporate purposes. This non-dilutive financing extends the loan maturity to 2029, enhances TScan’s financial flexibility, and supports its ongoing development efforts in advancing cancer therapies, potentially benefiting patients and investors.